The Board of Directors of the Wilson Disease Association (WDA) does not make medical recommendations to its members. For this reason the WDA depends on the expertise of its Medical Advisory Committee (MAC) to advise the leadership of the WDA on medical and scientific aspects of Wilson disease. Members of the MAC have relevant professional degrees, knowledge and demonstrated clinical and/or scientific expertise pertinent to Wilson disease.

The MAC has reviewed all data on Gluzin, provided by the manufacturer, and has made the following recommendations:

1. The product Gluzin is an over-the-counter zinc product that is prepared from zinc gluconate. The preparation of this product without extra filler may be an improvement from other over-the-counter zinc gluconate products available. The product information supplied by the manufacturer suggests that the range of zinc content in the capsules closely approximates the stated dosage of the zinc.

2. This Zinc compound is not FDA approved for the treatment of Wilson Disease, and its manufacture and ongoing quality controls with regard to pill-to-pill variability, content, contaminants and consistency are not supervised or regulated by the FDA or by the WDA, its medical advisory board, or the physicians it recommends. The contents of the pills and quality controls are the sole responsibility of the manufacturer.

3. No clinical and laboratory data on human subjects from this medication are available for review and therefore any patient that uses this zinc compound (or any other over-the-counter zinc product) should undergo testing under their physician's supervision to determine that they continue to absorb the zinc properly and that their examinations and testing, in particular testing for copper status, remains stable and within the therapeutic range.